Abstract：Objective To investigate the protective effect of Sertraline Hydrochloride Tablets combined with Risperidone on the brain of residual schizophrenia. Methods A total of 70 patients with residual schizophrenia who were diagnosed and treated in the Third People’s Hospital of Fuyang City, Anhui Province from June 2016 to June 2019 were selected and divided into two groups according to random number table method: the combined treatment group (35 cases, Sertralin Hydrochloride Tablet and Risperidone treatment) and the control group (35 cases, Risperidone treatment). The positive and negative symptom scale (PANSS) positive, negative and total scores and the simple mental strength scale (MMSE), before treatment and six months and 12 months after treatment were compared. Results Six months after treatment, PANSS positive, negative and total scores were lower in both groups than that before treatment, while MMSE score was higher than that before treatment (P ＜ 0.05). At 12 months after treatment, PANSS positive, negative and total scores were lower than those before treatment and after six months of treatment, while MMSE score was higher than those before and after six months of treatment (P ＜ 0.05). At six months after treatment, PANSS positive and total score in the combined treatment group were lower than those in the control group, while MMSE score was higher than that in the control group (P ＜ 0.05). At 12 months after treatment, the positive, negative and total scores of PANSS in the combined treatment group were lower than those in the control group, while the MMSE score in the combined treatment group was higher than that in the control group (P ＜ 0.05). Conclusion Sertraline Hydrochloride Tablets combined with Risperidone can effectively reduce PANSS score and increase MMSE score in patients with residual schizophrenia, and have a brain protective effect on patients with residual schizophrenia.
京公网安备 11010502046598号